VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce with the dealer licence being granted which was previously announced on December 28, 2017, the Company has now engaged a branding firm in the development of label and package design in compliance of Health Canada regulations. Veritas is applying to amend Cannevert’s Dealer Licence such that the Company can package Cannevert products including CTL-X for sale to licensed producers in Canada and for the export market.
CBD Strategy Group, a cannabis brand and marketing firm, has been retained to help develop brand strategy and guidelines around compliant packaging and labeling for both cannabis import and export.
“We are very excited to work with Dr. Lui Franciosi and the entire Veritas Pharma team. The work that will be done through Cannevert Therapeutics to develop clear, systematic, scientific and batch-to-batch therapeutic cannabis solutions is exciting and exactly where the industry needs to go. As regulation continues to define itself, our goal is to provide Cannevert Therapeutics with brand support and insights on market requirements, which includes compliant label and package development,” said Jenn Larry, President, CBD Strategy Group.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.
Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP. For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors
"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.